secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001193125-24-268497
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest
--------------------------------------------------------------------------------

- Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.
- XOMA gets low- to mid-single-digit net royalty on seralutinib commercial sales.
- XOMA retains up to $25M of future milestone payments tied to seralutinib.
- Seralutinib (Phase 3 PAH) readout expected Q4 2025; developed by Gossamer/Chiesi.
- This is XOMA's second whole-company acquisition in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/0001193125-24-268497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/d900185d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-268497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer